The eluates (5��L) containing viral nucleic acids were analyzed by real-time PCR on the LightCycler instrument using the LightCycler selleckchem Tipifarnib Parvovirus B19 Quantification Kit (Roche Diagnostics), according to the manufacturer’s instructions. Samples positive for PV B19 DNA were also tested to detect the possible presence of concomitant active viral infections. Detection and quantification by real-time PCR method of hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV), were performed using the fully automated system COBAS Ampliprep/COBAS TaqMan (Roche Diagnostics). For Cytomegalovirus (CMV) detection, the COBAS Amplicor CMV Monitor Test was used (Roche Diagnostics), with nucleic acid extraction performed on the Ampliprep instrument using the TNAI kit (Roche Diagnostics).
For Polyomavirus JC/BK, Epstein-Barr virus (EBV), and Herpes simplex virus type 1 and type 2 (HSV) detection and quantification, viral DNA was extracted by the automated MagNA Pure LC system (Roche Diagnostics) according to the manufacturer’s instructions and the real-time PCR reactions were performed on the LightCycler instrument using LightMix Kit Polyomaviruses JC and BK (TIB MOLBIOL, Berlin, Germany), LightCycler EBV Quantification Kit (Roche Diagnostics), and LightCycler HSV 1/2 Detection Kit (Roche Diagnostics), respectively. Statistical analysis was performed using Fisher exact test, with P �� 0.05 required for significance.3. Results and DiscussionThe results are summarized in Table 1. Overall, out of 64 KT recipients, 2 (3.
12%) were affected by active Parvovirus B19 infection, both belonged to the nonanemic patients group. In particular, the prevalence of PV B19 infection was 4% (2/50) in nonanemic patients compared to 0% (0/14) in anemic patients. This result is not supported by statistical significance (Fisher exact test P = 0.6), probably because of the small sample size.Table 1Prevalence of Parvovirus B19 in kidney transplant recipients, from January to July 2008, Latina, Italy.The first patient affected by active PV B19 infection was a 60-years-old man on dialysis treatment since 1992 who received a deceased donor kidney in 1998. He was using cyclosporine and mycophenolate-mofetil as immunosuppressive drugs and his value of serum creatinine was 1.3mg/dL. During PV infection his hematocrit was 37% from a baseline of 44% with an hemoglobin value decreased from 14 to 12.
4g/dL and PV B19 viremia of 1 �� 105 genome copies/reaction. Before the diagnosis of Parvovirus B19 infection, he suffered from Drug_discovery myalgia, abdominal pains, arthralgias, and recurrent fevers. After treatment with Immunoglobulin (IVIG), viremia fell below detection limit and his hematocrit and hemoglobin levels returned to normal.The second patient was a 62-years-old man who received a deceased donor kidney in 2001, after 4 years of dialysis.